Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

US sticks by rosiglitazone

The US Food and Drug Administration has decided to keep rosiglitazone on the market, despite new research adding to concerns over its effect on the heart.

An advisory panel convened by the FDA voted 22 to one to allow continued marketing of the drug, and 20 to three against a suggestion that available studies showed a signal of harm.

But the panel did recommend the drug should come with strong warnings over its potential risks.

The safety of rosiglitazone has been called into question by a number of studies pointing to increased cardiovascular risk, including new research suggesting it could raise the risk of heart failure.

A US study published in Diabetes Care concluded the risk of heart failure might be up to 100% higher in patients taking glitazones such as rosiglitazone.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say